Find a PhysicianContact Us    facebook_icon40.png  twitter_icon40.png  youtube_icon40.png
The Cancer Center

Services and Staff

Support Groups

Clinical Trials 

Patient Profiles

Learning Center

Memorial Hospital of Rhode Island
The Cancer Center
111 Brewster Street
Pawtucket, RI 02860

(401) 729-2700

2012 Cancer Annual Report

Click here to learn about donation opportunities at The Cancer Center
Clinical Trials
Memorial Hospital of Rhode Island
The Cancer Center
Clinical Trials
(See key at end of page for descriptions of study sponsors)

Phases of Clinical Trials
Most clinical research that involves the testing of a new drug progresses in an orderly series of steps, called phases. This allows researchers to ask and answer questions in a way that results in reliable information about the drug and protects the patients. Most clinical trials are classified into one of three phases:

  • Phase I trials: These first studies in people evaluate how a new drug should be given (by mouth, injected into the blood, or injected into the muscle), how often, and what dose is safe. A phase I trial usually enrolls only a small number of patients, sometimes as few as a dozen.

  • Phase II trials: A phase II trial continues to test the safety of the drug, and begins to evaluate how well the new drug works. Phase II studies usually focus on a particular type of cancer.

  • Phase III trials: These studies test a new drug, a new combination of drugs, or a new surgical procedure in comparison to the current standard. A participant will usually be assigned to the standard group or the new group at random (called randomization). Phase III trials often enroll large numbers of people and may be conducted at many doctors' offices, clinics, and cancer centers nationwide
  • In addition, after a treatment has been approved and is being marketed, the drug's maker may study it further in a phase IV trial. The purpose of phase IV trials is to evaluate the side effects, risks, and benefits of a drug over a longer period of time and in a larger number of people than in phase III clinical trials. Thousands of people are involved in a phase IV trial.


Title: Neratinib/Xeloda vs Lapatinub/Xeloda in 2nd and 3rd line HER2+ Metastatic Breast Cancer
Phase: III
Modality: Chemotherapy/Immunotherapy
Sponsor: PUMA


Title: Adjuvant chemotherapy with or without Avastin for resected Stage IB-IIIA NSCLC
Phase: III
Modality: Chemotherapy and biological
Sponsor: CTSU

Title: Sunitinib or Placebo following 4 cycles of platinum based chemotherapy in Stage IIIB-IV NSCLC
Phase: III
Modality: Chemotherapy and immunotherapy
Sponsor: CALGB

Title: AVALL: Progression of Metastatic Non-Small Cell Lung Cancer on Maintenance Avastin-Continue Avastin or not? 
Phase: III
Modality: Biological
Sponsor: GenentechSWOG

Title: Stereotactic Body Radiation Therapy for consolidation after Chemotherapy/Radiation Therapy Therapy in Stage III Lung Cancer
Phase: II
Modality: Radiation Therapy
Sponsor: BeUOG

Title: Oral LDk378 vs standard chemotherapy for patients with ALK-rearranged advanced Non-Small Cell Lung Cancer
Phase: III
Modality: Chemotherapy
Sponsor: Novartis


Title: 6 or 12 cycles of adjuvant Folfox plus either Celecoxib or placebo for resected Stage III (note +) Colon Cancer
Phase: III
Modality: Chemotherapy
Sponsor: CALGB

Title: FOLFOX-A for Metastatic/Advanced Pancreatic Cancer
Modality: Chemotherapy
Sponsor: BrUOG

Title: Cabazitaxel/Prednisone 20mg vx Cabazitaxel/Prednison 25 mg q 3 weeks for second line Metastatic Prostate Cancer 
Phase: III
Modality: Chemotherapy
Sponsor: S/A EFC


Title: Lab Study for AML/ALL/MDS/CML: Genetic Alterations in Hematopoietic Cells using blood and bone marrow cells
Phase: NA
Modality: Lab Study
Sponsor: RWMC


Title: Eribulin Mesylate and Cetuximab for Advanced Head and Neck Cancer following one prior therapy
Phase: I
Modality: Chemotherapy
Sponsor: BrUOG

Title: Adjuvant Ipilimumab vs Interferon for resected High-Risk Melanoma
Phase: III
Modality: Immunotherapy, Biological
Sponsor: CTSU

Title: Assessment of the effectiveness of Chemotherapy teaching
Phase: NA
Modality: Observational
Sponsor: BrUOG

Title: Evaluate the safety of IVIG (Octagam) with special emphasis of TEE
Phase: III
Modality: Biological
sponsor: OctaPharma

Description of study sponsors:

    * BrUOG = Brown University Oncology Group
    * CALGB = Cancer and Leukemia Group B
    * CTSU = Clinical Trials Support Unit
    * IBCSG = International Breast Cancer Study Group
    * MHRI = Memorial Hospital of Rhode Island
    * NSABP = National Surgical Adjuvant Breast and Bowel Project
    * RTOG = Radiation Therapy Oncology Group
    * SWOG = Southwest Oncology Group

(Revised 6/4/13)
Have a Question? Call 1-800-647-4362 to speak with our physician referral service


 Search for a Doctor

Memorial Info

Care New England
  Butler Hospital
  Kent Hospital
  VNA of CNE
  Women & Infants

Contact Us 

Locations & Directions 
Departments & Programs
  Emergency Services
  Family Care Center
  Hernia Center
  Stroke Center
  Surgical Services
  View all services

Patient Guide
  Downloadable Guide
  Visitors Information
  Medical Records
  Questions & Concerns

Education & Research
  Family Medicine Residency
  Internal Medicine Residency
  School of Nurse Anesthesia
  Podiatric Surgery Residency
 Follow Us Online at:

facebook_icon40.png  twitter_icon40.png  youtube_icon40.png  
© 2014 MHRI, 111 Brewster Street, Pawtucket, RI 02860 (401) 729-2000
Site credits & acknowledgements.